What is the mortality risk of patients with Chronic Heart Failure taking Ivabradine compared to placebo?
The mortality risk of patients with Chronic Heart Failure taking Ivabradine compared to placebo was assessed in 1579 participants over follow up and the quality of the evidence was graded as very low due to risk of bias and imprecision (from 31 fewer to 29 more). The relative effect was found to be very low (from 24 fewer to 0 more). The anticipated absolute effects of risk with placebo and risk difference with Ivabradine (95% CI) were also found to be very low.